H ypertensive disorders of pregnancy are a leading cause of maternal and fetal morbidity and mortality throughout the world.
H ypertensive disorders of pregnancy are a leading cause of maternal and fetal morbidity and mortality throughout the world. 1 These disorders include gestational hypertension, chronic hypertension, preeclampsia, and chronic hypertension with superimposed preeclampsia. Preeclampsia is particularly known for the complexity of its clinical presentation. It is diagnosed by new-onset hypertension occurring during the second half of pregnancy along with a range of cardiovascular, renal, visual, or neural alterations. 2 As removal of the placenta is currently the only steadfast intervention to limit progression of maternal symptoms 3 and the retained placenta is associated with postpartum preeclampsia, 4 it is believed that the ischemic placenta plays a central role in the pathogenesis of preeclampsia. In support of a role for placental ischemia in the development of hypertension in preeclampsia, several experimental models of surgical-or environment-induced placental ischemia/hypoxia have vascular dysfunction, hypertension, and other neurohumoral abnormalities routinely seen in women with preeclampsia. 5 While human and experimental animal studies have focused on placental ischemic disease in the pathogenesis of preeclampsia, less is known about how established risk factors impact this hypertensive pathway. This includes overweight and obesity. [6] [7] [8] The number of overweight and obese women of reproductive age is rising [9] [10] [11] [12] ; this is alarming because the incidence of preeclampsia progressively climbs with increasing prepregnancy body mass index (BMI [kg/m 2 ]). Indeed, the incidence of preeclampsia was shown to be 3% in normal weight gravidas (BMI=18.5-24.9), 7% in class I obesity (BMI=30-34.9), 9% in class II (BMI=35-39.9), 11% with class III obesity (BMI=40-49.9), and 13% in super-obese women (BMI=50) without chronic hypertension. 8 Although these observational studies have established an association between obesity and preeclampsia, less is understood about how obesity influences the development of placental ischemia-induced hypertension. It has been suggested that obesity increases the risk of developing preeclampsia by increasing the susceptibility of the maternal cardiovascularrenal system to hypertension produced by placental ischemic and hypoxic stimuli. 13, 14 The increase in blood pressure associated with obesity is believed to be partly mediated by increases in sympathetic nervous system (SNS) activity as a result of MC4R (melanocortin-4 receptor) activation. This principle stems from studies showing that MC4R plays a dual role in cardio-metabolic function by regulating food intake and blood pressure. Obese humans and experimental animals having genetic deficiency or pharmacological antagonism of this receptor system have increased food intake. 15, 16 This results from an attenuated ability of the satiety hormone, leptin, to signal to MC4R in the central nervous system to regulate food intake. 17 Although reduced MC4R signaling promotes obesity, studies in males show this increased body weight and fat mass is not accompanied by hypertension via suppression of the SNS. 18 Interestingly, emerging evidence suggests a role for the SNS in modulating placental ischemia-induced hypertension. Studies in humans and experimental animals have reported that activity of the SNS is increased during preeclampsia. 19, 20 Moreover, we recently found that adrenergic receptor blockade attenuated the development of placental ischemia-induced hypertension in rats with reduced uterine perfusion pressure (RUPP). 21 In anesthetized rats, antagonism of MC3/4R in the brain reduced blood pressure and SNS activity more so in pregnant versus nonpregnant groups, suggesting increased blood pressure dependency on this system during gestation. 22 Investigators have also shown that obese MC4R-deficient (def) offspring generated from breeding MC4R heterozygous-def parents are protected against maternal insults whereby they have attenuated hypertension after exposure to an in utero high-fat diet or placental ischemia. 23, 24 However, these studies did not assess the impact of MC4R deficiency on placental ischemia-induced hypertension. While it is thought that obesity may exacerbate the blood pressure response to placental ischemia, increases in body weight associated with MC4R deficiency may not have this predicted effect because MC4R deficiency also attenuates activity of the SNS. Therefore, we tested the hypothesis that placental ischemia-induced hypertension is attenuated in MC4R-def obese pregnant rats by comparing the effects of RUPP on blood pressure between MC4R +/+ (wild-type [WT]) and MC4R +/K314X (heterozygous-def) pregnant rats. We used the RUPP model of placental ischemia as a hypertensive second-hit to delineate whether MC4R deficiency attenuates placental ischemia-induced hypertension although they have elevated body weight, fat mass, and obesity-related metabolic factors during pregnancy. This would suggest that MC4R signaling is important for the development of placental ischemiainduced hypertension in obese pregnancies.
Methods
According to the Transparency and Openness Promotion Guidelines, the data that support the findings of this study are available from the corresponding author upon reasonable request.
Animals
All animal experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals with all animal-use protocols approved by The University of Mississippi Medical Center's Institutional Animal Care and Use Committee. Male and female MC4R +/K314X (heterozygous-deficient, MC4R-def) were obtained from Charles River Laboratories (Wilmington, MA) and used as founders for our colony. The colony was propagated by non-brothersister mating of heterozygous-def breeding pairs to preserve heterozygosity. 25 Experimental MC4R heterozygous-def and WT rats were produced from ≥3 different heterozygous breeding pairs. All rats were maintained on standard chow diet (Teklad 7013/NIH31; Indianapolis, IN) and water ad libitum. At weaning (3 weeks), all offsprings were placed on NIH31 diet and tails biopsied for genotyping. A timeline illustrating the details of rat production ( Figure S1 in the online-only Data Supplement) and experimental protocols ( Figure S2 ) can be found in the online-only Data Supplement.
MC4R Genotyping
The MC4R-def rat model was originally developed by an ENU (N-ethyl-N-nitrosourea)-induced mutation in Wistar Hannover rats, which resulted in a truncated form of the receptor with the inability to be expressed in the plasma membrane. 26 The mutation introduced an additional Ddel restriction site (CTNAG) within the MC4R gene. Thus, genotyping was performed using a restriction enzyme-based polymerase chain reaction assay using the primers: Forward: TGATCATGTGTAACGCTGTCAT, Reverse: TGACAAATTCTGCAGGTCTCT to amplify 177 bp fragment of Mc4r gene. The polymerase chain reaction product was subjected to Ddel enzyme restriction and genotyping was performed using Qiagen QIAxcel Advanced capillary electrophoresis system. For WT rats, Ddel-treated polymerase chain reaction fragment generated 2 bands at 120 and 57 bases and homozygous MC4R-def rats gave 3 fragments at 106, 56, and 15 (unobserved).
Timed Pregnancies and RUPP Procedure
At ≈13 weeks old, WT or MC4R heterozygous-def females were mated with WT or MC4R heterozygous-def males, respectively, for the generation of timed-pregnant experimental rats. The observation of sperm in vaginal smears was indicative of gestational day (GD) 0. On GD 14, the RUPP procedure was performed, as described previously. 27 Briefly, a silver clip (0.203 mm, internal diameter) was placed around the subrenal abdominal aorta above the uterine arteries along with clips (0.1 mm, internal diameter) on branches of the ovarian artery in both uterine horns. The normal pregnant control group consisted of a Sham surgery with similar abdominal incision and suturing without clip placement.
Fat Mass Assessments
On GD 18, total body fat mass and total lean mass were examined using Echo-MRI-700 equipment (Echo Medical Systems, Houston, TX). For this, rats were placed in restraint cages and the average of 2 scans recorded for each rat. On GD 19, retroperitoneal and perirenal fat were collected and wet weights recorded to assess visceral fat mass.
Food Intake
Food intake was assessed between GD 17 and 18 after recovery from surgeries on GD 14 and before conducting catheterizations for blood pressure measurements on GD 18.
Maternal Blood Pressure Assessment
On GD 18, indwelling catheters were implanted in the left carotid artery and exposed at the nape of the neck. Catheters consisted of V/1 tubing attached to V/3 tubing (Scientific Commodities, Lake Havasu City, AZ). Approximately 2.5 cm of the V/3 end of the catheter was inserted into the carotid. Catheters were filled with sterile heparin-0.9% saline solution (300 mg/mL; Pfizer, New York City, NY) and stoppered with a stainless steel catheter plug (SP22/12; Instech Laboratories, Plymouth Meeting, PA) to maintain patency. On GD 19, conscious mean arterial blood pressure and heart rates were measured, as described previously. 28 For this purpose, rats were placed in restrainers (Kent Scientific Corp, Torrington, CT) and catheters connected to pressure transducers (MLT0699; ADInstruments, Colorado Springs, CO) coupled to a computerized data acquisition system (PowerLab, ADInstruments). Readings were calibrated on every rat then data acquired at 1 K/s. Once blood pressure readings stabilized (≈1 hour), ≈10 minutes of mean arterial blood pressure (MAP) and heart rate data were collected and averaged. The percentage increase 
Blood Collection and Pregnancy Biometrics
On GD 19, a midline incision was made and uterine horns with fetuses exteriorized. Blood was collected from the abdominal aorta into Vacutainer K 2 EDTA tubes (BD, Franklin Lakes, NJ), spun at 2500 rpm for 12 minutes at 4°C, and plasma stored at −20°C. It was ensured that each fetus and matching placenta were weighed and recorded as individual fetal-placental units. Average fetal and placental weights were calculated per rat then averaged for each experimental group. Total viable or resorbed fetuses were noted. Percent fetal resorption = (number of resorbed fetuses/total number of fetuses)×100. Placental sufficiency = average viable fetal weight/average placental weight for each dam, as a surrogate measure of the nurturing capacity of the placenta, as previously described in humans. 29 
Biochemistry
Plasma levels of the adipokines leptin and adiponectin were examined using Quantikine ELISA kits from R&D Systems (Minneapolis, MN, MOB00 and RRP300, respectively). As reduced bioavailability of PlGF (placental growth factor) mediates the development of placental ischemia-induced hypertension, 30 plasma PlGF levels were also quantified by an ELISA kit from R&D Systems detecting mouse PlGF-2 (Minneapolis, MN-MP200). Using the National Center for Biotechnology Information Protein Basic Local Alignment Search Tool software, it was found that mouse and rat PlGF-2 have 91% alignment (https://www.blast.ncbi.nlm.nih.gov/www.Blast.cgi).
Statistical Analysis
Data were graphed and analyzed using GraphPad Prism version 7.0 (La Jolla, CA). Data are presented as mean±SEM. Statistically significant differences were defined as P<0.05. Two-way ANOVA tests were conducted followed by Tukey's multiple comparisons tests and the results are inset in each graph. Symbols are included in these insets to highlight the differences between factors if a statistical interaction was not detected.
Results

Impact of MC4R Deficiency on Placental IschemiaInduced Hypertension
At GD 19, normal pregnant MC4R-def rats had greater MAP levels than their normal pregnant WT counterparts ( Figure 1A ). Placental ischemia, as induced by the RUPP procedure, produced frank hypertension in WT rats compared with normal pregnant WT control rats by GD 19 ( Figure 1A ). In contrast, placental ischemia-induced hypertension was significantly attenuated in the MC4R-def rats ( Figure 1A) . Indeed, this attenuated hypertensive response was highlighted by examining the percentage change in MAP, which further revealed that RUPP produced a greater increase in blood pressure in WT rats and a lesser response in MC4R-def rats ( Figure 1B) .
Heart rate was not significantly different (P=0.56) between normal pregnant WT (425±7 bpm) or MC4R-def pregnant rats (430±6 bpm) and RUPP did not impact this parameter in WT (443±6 bpm) or MC4R-def pregnant rats (434±11 bpm; P=0.10). Heart weight-to-body weight ratio was also not different (P=0.08) between the normal pregnant groups (WT: 0.002±0.00007 versus MC4R-def: 0.002±0.00005) but RUPP increased (P=0.0003) this measure similarly in both WT (0.003±0.0001) and MC4R-def rats (0.002±0.0001). Figure 2 shows the impact of MC4R-heterozygous deficiency on maternal body weights by GD 19. When compared with normal pregnant WT rats, MC4R-def pregnant rats had significantly greater body weight by ≈30 g (Figure 2A ). The RUPP procedure reduced maternal body weight in both WT and MC4R-def rats likely because of reduced fetal weights and resorptions, but body weight remained greater in the latter RUPP group (Figure 2A ). Analogous differences were found for total maternal fat mass ( Figure 2B ) and isolated visceral fat ( Figure 2C ).
Maternal Biometrics
Echo-MRI revealed that maternal lean body mass was similar between normal pregnant groups (WT: 266±3 g versus MC4R-def: 272±4 g, P=0.010) and was reduced in both strains after RUPP (WT: 229±7 g versus MC4R-def: 248±5 g, P<0.0001). Food intake was assessed between GD 17 and 18, and this parameter was similar between normal pregnant groups (WT: 18±1 g versus MC4R-def: 21±2 g, P=0.27) but was reduced to a greater extent (P=0.037) in RUPP MC4R-def rats (13±2 g) than RUPP WT rats (19±2 g).
Circulating Obesity-Related Metabolic Factors
Leptin levels, overall, were significantly elevated in the MC4R-def groups versus the WT groups and RUPP did not modify these levels ( Figure 3A) . Adiponectin levels were similar in the MC4R-def versus WT rats and were reduced in parallel by RUPP in both groups ( Figure 3B ). Insulin levels, overall, were significantly elevated in the MC4R-def groups versus the WT groups and RUPP did not modify these levels ( Figure 3C ). Figure 4 presents fetal and placental biometrics in the 4 experimental groups at GD 19. Average fetal weights were comparable between normal pregnant WT and MC4R-def rats ( Figure 4A ). The RUPP procedure produced intrauterine growth restriction similarly in both WT and MC4R-def groups ( Figure 4A ). Similar trends were found for total fetal weights between WT (26±1 g) and MC4R-def (24±1 g) normal pregnant rats and RUPP significantly (P<0.05) reducing these values in WT (11±1 g) and MC4R-def (12±1 g) pregnant rats. There was no difference in the number of live fetuses in normal pregnant WT (14±1) versus MC4R-def rats (13±1) and these numbers were similarly reduced by RUPP in WT (7±1) and MC4R-def rats (7±1). Thus, RUPP-induced fetal resorption rates were similar between both genotypes ( Figure 4B ).
Fetal and Placental Biometrics
Average placental weights were comparable between normal pregnant WT and MC4R-def rats at GD 19 and were not affected by RUPP ( Figure 4C ). Similar trends were found for total placental weights between WT (6.4±0.3 g) and MC4R-def (6.2±0.2 g) pregnant rats and RUPP significantly (P<0.05) reducing these values in WT (2.9±0.4 g) and MC4R-def (3.3±0.4 g) pregnant rats. As for placental sufficiency, which is as a surrogate marker of the nutritive capacity of the placenta, there was no difference detected between either normal pregnant strains but was reduced to similar values among both genotypes after RUPP ( Figure 4D ).
Bioavailable PlGF Levels
Circulating levels of PlGF were comparable between normal pregnant WT and MC4R-def strains but were significantly reduced by similar magnitudes by RUPP in both strains ( Figure 5 ).
Discussion
The novel finding of the present study is that obese pregnant rats because of MC4R deficiency have attenuated placental ischemia-induced hypertension. Our data indicate that while MC4R-def rats compared with WT rats have higher blood pressure during normal pregnancy, placental ischemia-induced hypertension is attenuated in MC4R-def pregnant rats. This attenuated blood pressure response occurred despite elevations in the obesity-related metabolic factors leptin and insulin in the obese pregnant rats and similar decreases in adiponectin and PlGF levels in response to RUPP between both MC4R-def and WT pregnant rats. Thus, obese pregnancies associated with abnormal MC4R signaling may be less susceptible to the development of placental ischemia-induced hypertension.
While human and experimental animal studies have focused on placental ischemic disease in the pathogenesis of preeclampsia, less is known about how established risk factors such as obesity impact the link between placental ischemia and blood pressure regulation during pregnancy. Several epidemiological studies have established a strong association between obesity and preeclampsia. 6, 8, 31, 32 Ours is the first and only study comparing maternal blood pressure under normal pregnant conditions and the hypertensive response to placental ischemia in a model of obesity. We used a genetically obese pregnant rat model having heterozygous MC4R deficiency. The purpose for using a genetic model of obesity in rats was based on our previous studies where there were no dramatic changes in body weight or fat mass after high-fat diet feeding in female pregnant rats. 33, 34 Other studies suggest that high-fat diet increases central MC4R signaling, 35 but it has not been examined whether high-fat feeding or obesity alters placental ischemia-induced hypertension via MC4R signaling. In the current study, we set forth to explore the importance of MC4R in control of blood pressure during normal pregnancy and in response to RUPP. In MC4R-def pregnant rats, we previously showed and confirmed here that they have elevated body weight, fat mass, and blood pressure under normal pregnant conditions. 34 Moreover, our novel finding is that MC4R-def pregnant rats have attenuated placental ischemia-induced hypertension. The fact that not all obese pregnant women develop preeclampsia 32 suggests that obesity increases the susceptibility of the maternal cardiovascular system to hypertension produced by placental ischemic and hypoxic stimuli in only a portion of women, for instance those possibly having greater expression of MC4R. The epidemiological information about rates of altered expression of MC4R in obese women is meager. These are important studies requiring investigation, as our data suggest that obese pregnant women with MC4R deficiency have attenuated placental ischemiainduced hypertension in preeclampsia. Therefore, it is possible that certain forms of obesity associated with reduced MC4R signaling in the SNS may have an attenuated response to ischemic and hypoxic stimuli to the placenta and explain why, although obesity is thought to be a major risk factor for preeclampsia, some obese pregnant women do not develop severe preeclampsia or accompanying preeclampsia-related adverse outcomes. 36 This contention is based on previous reports that obese humans and experimental animals having genetic deficiency or pharmacological antagonism of MC4R activation are protected against the development of hypertension via suppression of the SNS. 37 However, there has been a lack of human or experimental animal studies focused on assessing whether altered MC4R expression impacts the development of hypertension during pregnancy. We tested the hypothesis that placental ischemia-induced hypertension is attenuated in MC4R-def pregnant rats by comparing the effects of RUPP on blood pressure between MC4R WT and MC4R heterozygous-def pregnant rats. MC4R heterozygousdef rats were used because of the low success rate of obtaining pregnant MC4R homozygous-def rats. Heterozygosity of the MC4R gene in humans is associated with increased food intake and is one of the most common forms of monogenetic obesity in humans. 38 Sex differences have not been a focus of these genetic studies. The majority of studies using MC4R-def rats and mice have been conducted in males, where it was demonstrated that this receptor mediates the blood pressure response to hypertensive stimuli, including increased circulating levels of the adipokine, leptin, via activation of the SNS. 17, [39] [40] [41] [42] Leptin crosses the blood-brain barrier to target neurons expressing the leptin receptor to stimulate the release of α-melanocyte-stimulating hormone, which acts via MC4R expressed on second-order neurons to elicit sympathetic nerve activity (SNA) toward the periphery. Fewer studies have focused on the importance of MC4R in blood pressure regulation in females, especially during normal pregnancy and preeclampsia.
MC4R-def rats have increased blood pressure during normal pregnancy. On the surface, our blood pressure data in normal pregnant MC4R-def rats seem to contrast what has been demonstrated with MC4R deficiency in male rodents whereby increases in circulating levels of the obesity-related metabolic factor, leptin, led to downstream activation of central MC4R to promote SNA and hypertension. 18 However, it is important to note that our pregnancy studies used heterozygous MC4R-def rats that were not completely deficient in the receptor. Therefore, based on findings from others suggesting that SNS activity is increased during normal pregnancy in humans 43, 44 ; that MC4R control of blood pressure and SNS activity are increased in pregnant versus nonpregnant rats 22 ; a vast amount of data that central MC4R signaling elicits sympathetic outflow; and leptin levels are increased in our obese hypertensive pregnant rats, we propose that obesity-related metabolic factors target central MC4R to chronically stimulate SNA and increase blood pressure in our obese hypertensive pregnant rats under normal pregnant conditions. The MC4R-def rats in this study had a global deficiency in the receptor. Although this might be a limitation of the present study, it is not evident that MC4R is expressed in placental tissue 45 or that MC4R in the periphery controls blood pressure. Whereas, a body of evidence using brain-specific knockout mice and intracerebroventricular administration of antagonists to this receptor system, suggests that MC4R mediates its impact on blood pressure via elegant neural pathways. 23, 40, 46, 47 Our study was not designed to examine brain-specific deficiency of MC4R on SNS outflow and downstream blood pressure regulation during pregnancy. Nor did this study delve into the timeframe for the development of hypertension in our obese pregnant model. We previously published that prepregnancy body weight is greater in MC4R-def versus than in WT rats. 34 In the current study, our focus was on the impact of MC4R deficiency on placental ischemia-induced hypertension toward the end of pregnancy. We did not assess body weight or blood pressure before pregnancy in the group of rats included in this study. As there are human data to suggest that elevated prepregnancy body weight is an independent risk factor for hypertension during pregnancy, 48 future studies involving caloric restriction and biotelemetry blood pressure recordings should be conducted to deduce the importance of increased body weight, fat mass, and obesity-related metabolic factors on chronic blood pressure regulation in obese MC4R-def rats throughout pregnancy.
We previously observed that chronic infusion of the obesity factors leptin or insulin into once normotensive pregnant Sprague-Dawley rats elicited increases in blood pressure. 49, 50 The levels of these factors were not altered by RUPP in MC4R-def pregnant rats; thus, they remained elevated after the procedure compared with WT pregnant rats. Although the RUPP procedure reduced body weight and fat mass in both MC4R-def and WT pregnant rats, it is important to note that adiposity was still higher in RUPP MC4R-def over RUPP WT levels. As a result, we found a combination of elevated obesity-related metabolic factors coupled to a significant reduction in circulating PlGF. Placental ischemia and preeclampsia in humans and experimental animal models are marked by altered circulating levels of angiogenic factors, like PlGF. 21, 51 Placental ischemia elicits the release of antiangiogenic factors from the placenta; this includes the sFlt-1 (soluble fms-like tyrosine kinase-1). 52 Once in the circulation, sFlt-1 binds and reduces bioavailable PlGF and VEGF (vascular endothelial growth factor). 53 Angiogenic factors, like PlGF and VEGF, are important for maintenance of maternal vascular health. PlGF plays an increased role in promoting vasorelaxation during normal pregnancy via action on its receptor, VEGFR1 (VEGF receptor 1), whereas VEGF isoforms largely bind to VEGF2 to induce relaxation via stimulation of nitric oxide synthase. 54 We previously showed that RUPP rats have reduced levels of PlGF and administration of this factor abolishes their hypertension. 30 These data suggest that RUPP-induced reductions in PlGF mediate this hypertensive pathology. In the current study, RUPP significantly reduced plasma levels of PlGF in WT rats, which is indicative of vascular dysfunction and hypertension. Interestingly, PlGF levels were similarly reduced in RUPP WT versus MC4R-def rats. Even so, MC4R-def pregnant rats presented with an attenuated placental ischemia-induced hypertensive response. Our data are reminiscent to those of da Silva et al 40 who showed in male rats that chronic pharmacological blockade of these receptors directly in the brain attenuates the hypertensive response to systemic vascular dysfunction after nitric oxide synthase inhibition, which was produced by intravenous infusion of the nonselective nitric oxide synthase inhibitor, L-NAME (L-N G -nitroarginine methyl ester). Collectively, these data suggest that, even in the face of reduced PlGF bioavailability, reduced nitric oxide synthase, and vascular dysfunction, MC4R deficiency attenuates the maternal hemodynamic response to placental ischemia produced by the RUPP procedure. Regardless of this combination of placental ischemic and obesity milieus that would be hypothesized to exaggerate blood pressure in MC4R-def RUPP rats, we did not find exaggeration of RUPP hypertension in MC4R-def pregnant rats. These data suggest that deficiency of MC4R attenuates the development of placental ischemia-induced hypertension using the RUPP model.
Our current research focused on the impact of MC4R deficiency on maternal blood pressure response to RUPP by using obese MC4R-def versus lean WT dams, but the consequences of this procedure on the health of the fetus from obese compared with lean dams remains to be elucidated. Frias et al 55 found in nonhuman primates that 4 years of high-fat feeding elicited maternal obesity associated with reductions in uterine artery and placental volume blood flow. However, they did not observe a change in fetal weights between the dietary groups. They did not examine maternal blood pressure. We found no differences in fetal weights under normal pregnant conditions and RUPP similarly reduced these values in our obese versus lean pregnant model. It is likely that the development of maternal hypertension in response to surgically induced RUPP is important to compensate for the reduced blood flow beyond the permanent clip placement during the surgery. The increased blood pressure would attempt to meet the metabolic demands of the fetal-placental unit and explain why there is not 100% fetal demise in the RUPP model. Interestingly, we found an attenuated blood pressure response to the RUPP procedure in MC4R-def versus WT rats, although there were no differences in the number of fetuses, fetal weights, or fetal resorptions between RUPP MC4R-def and RUPP WT rats by GD 19. It is unknown whether the lack of a rise in blood pressure in RUPP MC4R-def compared with WT rats leads to exaggerations in adverse fetal development at birth in offspring from RUPP MC4R-def versus RUPP WT dams. Follow-up studies should assess uteroplacental hemodynamics and outcomes in these offsprings at birth by examining birthweights, at which time crown-rump length and head-to-abdomen circumference will be measured. It has been found in human studies that a postnatal head circumference that is larger than abdominal circumference is indicative of intrauterine growth restriction. 56 RUPP similarly reduced fetal weight and increased fetal resorption rates in both MC4R-def and WT pregnant rats. Furthermore, there were parallel reductions in circulating levels of PlGF in both groups, which is indicative of comparable levels of placental ischemic disease. Therefore, we believe that the difference in blood pressure response to RUPP was not dependent on different levels of placental ischemia or hypoxia, but because of reduced expression of the MC4R in the deficient pregnant rat model. We propose that, during normal pregnancy, the available amount MC4R in the obese heterozygous MC4R-def pregnant rats is suitable to elevate blood pressure because of increased circulating levels of obesity-related metabolic factors that activate this receptor system to elicit SNS activity and increases in blood pressure. With regard to placental ischemiainduced hypertension, we previously reported that adrenergic receptor blockade attenuates the blood pressure response to RUPP. 21 Others found in nonpregnant rats that the pressor response to chronic central administration of an MC3/4R agonist was mediated by adrenergic activity. 57 We currently found that hypertension after RUPP was attenuated in MC4R-def pregnant rats. Collectively, these results implicate that a fully intact SNS is required to facilitate the maternal blood pressure response to a hypertensive second-hit of placental ischemia.
Hypertension in preeclampsia is associated with increases in SNA. Reyes et al 19 reviewed this topic at length by mentioning that such increases are a repeated observation in patients with preeclampsia. Others have also detected increased markers of SNA in surgical-and environment-induced experimental models of preeclampsia. For example, in RUPP dams or administration of lipopolysaccharide to pregnant rats, there was an enrichment of genes related to increased neuronal signaling and vasoconstriction in aortic tissue 58 and increased adrenergic receptor-induced vasoconstriction in systemic and renal circulations. 21 Moreover, cold-induced stress reduced mechanisms of placentation and elicited preeclampsia symptoms in rats. 59 Chronic hypoxia by placement of dams in hypobaric chambers programs for increased SNA in offspring as adults. 60 It is important to note that these are correlative findings without interventions to probe the contribution of the SNS in the maintenance of hypertension in preeclampsia. Whereas, we recently reported that RUPP rats have an enhanced effect to the blood pressure lowering effects of adrenergic receptor blockade. 21 Our findings suggest that MC4R and SNS signaling play a permissive role in the pathogenesis of placental ischemia-induced hypertension. Future studies should confirm whether MC4R plays a role in hypertension found in other experimental models of preeclampsia.
Perspectives
The prevalence of preeclampsia, a pregnancy-specific disorder of new-onset hypertension linked to placental ischemia, has increased over the past decades. This increase in prevalence is most likely related to an increase in many risk factors, including obesity. While obesity is a major risk factor for preeclampsia, not all obese pregnant women develop pregnancy-induced hypertension or preeclampsia. Our data indicate that while obese MC4R-def pregnant rats have higher blood pressure during pregnancy, placental ischemia-induced hypertension is attenuated in obese MC4R-def pregnant rats. Thus, obese women with abnormal MC4R signaling may be less susceptible to the development of placental ischemia-induced hypertension.
